SNDX Valuation

Syndax Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

15.850

+0.19(1.213%)1D

Overview
Forecast
Valuation
Earnings

SNDX Relative Valuation

SNDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNDX is overvalued; if below, it's undervalued.

Historical Valuation

Syndax Pharmaceuticals Inc (SNDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.78 is considered Undervalued compared with the five-year average of -7.81. The fair price of Syndax Pharmaceuticals Inc (SNDX) is between 85.04 to 113.81 according to relative valuation methord. Compared to the current price of 15.66 USD , Syndax Pharmaceuticals Inc is Undervalued By 81.59%.

Relative Value

Fair Zone

85.04-113.81

Current Price：15.66

81.59%

Undervalued

-5.96

Trailing

Forward

-6.13

EV/EBITDA

Syndax Pharmaceuticals Inc. (SNDX) has a current EV/EBITDA of -6.13. The 5-year average EV/EBITDA is -3.22. The thresholds are as follows: Strongly Undervalued below -17.07, Undervalued between -17.07 and -10.14, Fairly Valued between 3.71 and -10.14, Overvalued between 3.71 and 10.63, and Strongly Overvalued above 10.63. The current Forward EV/EBITDA of -6.13 falls within the Historic Trend Line -Fairly Valued range.

-5.80

EV/EBIT

Syndax Pharmaceuticals Inc. (SNDX) has a current EV/EBIT of -5.80. The 5-year average EV/EBIT is -6.51. The thresholds are as follows: Strongly Undervalued below -22.86, Undervalued between -22.86 and -14.69, Fairly Valued between 1.66 and -14.69, Overvalued between 1.66 and 9.84, and Strongly Overvalued above 9.84. The current Forward EV/EBIT of -5.80 falls within the Historic Trend Line -Fairly Valued range.

5.93

Syndax Pharmaceuticals Inc. (SNDX) has a current PS of 5.93. The 5-year average PS is 419.24. The thresholds are as follows: Strongly Undervalued below -1134.97, Undervalued between -1134.97 and -357.87, Fairly Valued between 1196.35 and -357.87, Overvalued between 1196.35 and 1973.46, and Strongly Overvalued above 1973.46. The current Forward PS of 5.93 falls within the Historic Trend Line -Fairly Valued range.

-15.12

P/OCF

Syndax Pharmaceuticals Inc. (SNDX) has a current P/OCF of -15.12. The 5-year average P/OCF is -7.12. The thresholds are as follows: Strongly Undervalued below -24.02, Undervalued between -24.02 and -15.57, Fairly Valued between 1.33 and -15.57, Overvalued between 1.33 and 9.78, and Strongly Overvalued above 9.78. The current Forward P/OCF of -15.12 falls within the Historic Trend Line -Fairly Valued range.

-15.04

P/FCF

Syndax Pharmaceuticals Inc. (SNDX) has a current P/FCF of -15.04. The 5-year average P/FCF is -7.47. The thresholds are as follows: Strongly Undervalued below -11.73, Undervalued between -11.73 and -9.60, Fairly Valued between -5.34 and -9.60, Overvalued between -5.34 and -3.21, and Strongly Overvalued above -3.21. The current Forward P/FCF of -15.04 falls within the Strongly Undervalued range.

Syndax Pharmaceuticals Inc (SNDX) has a current Price-to-Book (P/B) ratio of 8.88. Compared to its 3-year average P/B ratio of 3.75 , the current P/B ratio is approximately 136.74% higher. Relative to its 5-year average P/B ratio of 3.80, the current P/B ratio is about 133.68% higher. Syndax Pharmaceuticals Inc (SNDX) has a Forward Free Cash Flow (FCF) yield of approximately -22.18%. Compared to its 3-year average FCF yield of -13.50%, the current FCF yield is approximately 64.27% lower. Relative to its 5-year average FCF yield of -10.24% , the current FCF yield is about 116.56% lower.

8.56

P/B

Median3y

3.75

Median5y

3.80

-21.64

FCF Yield

Median3y

-13.50

Median5y

-10.24

Competitors Valuation Multiple

The average P/S ratio for SNDX's competitors is 121.99, providing a benchmark for relative valuation. Syndax Pharmaceuticals Inc Corp (SNDX) exhibits a P/S ratio of 5.93, which is -95.14% above the industry average. Given its robust revenue growth of 984.51%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SNDX.O

Syndax Pharmaceuticals Inc

Vera Therapeutics Inc

Loss

1.44B

JANX.O

Janux Therapeutics Inc

Abcellera Biologics Inc

Celldex Therapeutics Inc

332.74

-70.78%

1.44B

Performance Decomposition

Market capitalization of SNDX decreased by 22.87% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.50M to 37.96M.

The secondary factor is the Margin Expansion, contributed -90.27%to the performance.

Overall, the performance of SNDX in the past 1 year is driven by Revenue Growth. Which is more sustainable.

984.51%

3.50M → 37.96M

Revenue Growth

-90.27%

-1.94K → -189.28

Margin Expansion

-917.11%

0.49 → -4.03

P/E Change

-22.87%